Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Lymphoma, Follicular 6Sarcoma 3Rhabdoid Tumor 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Xanthogranuloma, Juvenile 1Wilms Tumor 1Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Nerve Sheath Neoplasms 1Melanoma 1Medulloblastoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1Inhibition, Psychological 1Histiocytosis, Langerhans-Cell 1Histiocytic Sarcoma 1Hepatoblastoma 1Glioma 1Ependymoma 1Chordoma 1

Interventions

pembrolizumab 2Radiotherapy 2Radiation 2Nivolumab 2Doxorubicin 2tazemetostat 1sotigalimab 1pazopanib 1Specimen Handling 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Ifosfamide 1CTLA-4 Antigen 1BO-112 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neurofibrosarcoma × tazemetostat × Clear all
NCT04917042 2026-06-04

Tazemetostat in Malignant Peripheral Nerve Sheath Tumors

University of Florida

Phase 2 Active not recruiting
10 enrolled 12 charts
Sarcoma

Inhibition, Psychological, Sarcoma, Nerve Sheath Neoplasms, Neurofibrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡